Innovate your generic pharmaceutical development efforts. Generic drug companies across the U.S. are engaged in formulation optimisation, bioequivalence method development, manufacturing process improvement and regulatory lifecycle enhancements. Many of these initiatives satisfy the criteria for the federal R&D Tax Credit under IRC §41, with additional state‑level opportunities.
Examples of qualifying activities in generic drug development
- Formulation optimisation Adjusting excipient blends, tablet coatings, dissolution profiles, or delivery formats to match reference drug.
- Manufacturing process improvement Pilot manufacturing runs, granulation/compression parameter adjustments, scale‑down models, blend uniformity studies.
- Bioequivalence/dissolution method development Developing or validating new analytical assays to show equivalence, side‑by‑side testing of generics vs innovator.
- Impurity/degradation pathway investigation Studying new impurity profiles, stability under different container/closure systems, generic stability challenge.
- Regulatory submission support & novel generics Developing biosimilar versions, reformulating for niche segments (paediatric, orphan indications), modifying process for fewer impurities or improved shelf‑life.
What qualifies as R&D in generic drug development?
To qualify, your generic‑development activities must:
- Aim at a permitted purpose — such as a new or improved generic formulation, more efficient manufacturing process, enhanced bioavailability, or novel regulatory‑submission method.
- Tackle technical uncertainty — for example: “Can this generic match the reference product’s dissolution and release profile under variable manufacturing conditions?”, “Will the scale‑up process maintain uniformity and impurity control across batches?”, “Can a novel excipient system deliver equivalent therapeutic effect while meeting regulatory criteria?”
- Use a process of experimentation — formulation trials, side‑by‑side generic vs. reference product testing, pilot manufacturing runs, scale‑up modelling, method validation comparisons.
- Be technological in nature, grounded in pharmaceutical science, formulation engineering, biopharmaceutics, process engineering or analytical chemistry.
Qualified Research Expenses (QREs)
Roles commonly involved in qualifying activities
- Formulation scientists and generic‑development specialists
- Biopharmaceutics and analytical chemists
- Process engineers working on manufacturing scale‑up or optimisation
- Quality/regulatory engineers managing validation studies
- Project leads coordinating formulation/manufacturing trials
What does not qualify
- Routine manufacture of generic products under established formulations without change or experimentation
- Standard production or regulatory filing without method development, testing, or technical uncertainty
- Administrative, marketing, sales or general business operations
- Capital equipment purchases that are not directly tied to a documented research experiment
Compliance and Documentation
Following the One Big Beautiful Bill Act (OBBBA) signed July 4, 2025, §174 now allows immediate expensing of domestic research expenses for tax years beginning on or after January 1, 2025. Taxpayers may also elect optional amortization under new §174A. Foreign research expenses must still be amortized over 15 years. This is separate from the §41 credit but impacts overall tax planning.
Maintain detailed records such as:
- Formulation trial logs, version history of excipient blends, dissolution/bioequivalence study results
- Pilot manufacturing runs, batch logs, scale‑up modelling reports, yield/scrap comparison data
- Analytical method validation logs, IP/trial design notes, side‑by‑side testing results
- Employee time tracking by project, supply usage logs tied to experiments These support the four‑part test of permitted purpose, technical uncertainty, process of experimentation and technological nature.
Frequently Asked Questions
Yes — when they engage in new or improved formulations, manufacturing process innovation, bioequivalence or analytical method development, not routine generic production.
Wages of development staff, trial formulation supplies, software or analytics tools, contract research costs with method validation or pilot manufacturing.
Routine manufacturing without innovation, generic substitution without development, purely operational or administrative tasks.
Track formulation iteration history, trial logs, pilot run data, employee project time logs, supply/test‑kit consumption tied to experiments.
Next Steps
Use our calculator to estimate your potential federal and state benefits
Schedule a consultation to structure your row crop research activities
If you are innovating in agriculture, you may already be doing R&D. Let's make sure you are rewarded for it.
Contact Strike Tax Advisory
Ready to maximize your R&D tax credits? Get in touch with our team of experts.
How much could I get back for
Generic Drug Development
?
